Rajesh Kumar
Stock Analyst at HSBC
(2.42)
# 2,411
Out of 5,170 analysts
33
Total ratings
40.91%
Success rate
4.1%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Downgrades: Reduce | $1,070 → $850 | $920.08 | -7.62% | 4 | Mar 17, 2026 | |
| PFE Pfizer | Maintains: Buy | $29 → $32 | $27.41 | +16.75% | 2 | Mar 17, 2026 | |
| BIIB Biogen | Maintains: Reduce | $143 → $150 | $182.31 | -17.72% | 2 | Mar 17, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $60 | $58.76 | +2.11% | 3 | Mar 17, 2026 | |
| ABBV AbbVie | Upgrades: Buy | $225 → $265 | $208.99 | +26.80% | 5 | Dec 10, 2025 | |
| NVO Novo Nordisk | Downgrades: Hold | n/a | $36.66 | - | 3 | Nov 24, 2025 | |
| IQV IQVIA Holdings | Upgrades: Buy | $195 → $235 | $165.38 | +42.10% | 2 | Oct 9, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $27.17 | +54.61% | 1 | Apr 25, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $464.46 | +44.25% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $188.63 | +48.44% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $460 | $282.69 | +62.72% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $29.16 | -55.41% | 1 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $52.14 | +86.04% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $88.45 | +40.20% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $114.37 | +7.55% | 1 | Jul 14, 2023 |
Eli Lilly and Company
Mar 17, 2026
Downgrades: Reduce
Price Target: $1,070 → $850
Current: $920.08
Upside: -7.62%
Pfizer
Mar 17, 2026
Maintains: Buy
Price Target: $29 → $32
Current: $27.41
Upside: +16.75%
Biogen
Mar 17, 2026
Maintains: Reduce
Price Target: $143 → $150
Current: $182.31
Upside: -17.72%
Bristol-Myers Squibb Company
Mar 17, 2026
Maintains: Hold
Price Target: $53 → $60
Current: $58.76
Upside: +2.11%
AbbVie
Dec 10, 2025
Upgrades: Buy
Price Target: $225 → $265
Current: $208.99
Upside: +26.80%
Novo Nordisk
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $36.66
Upside: -
IQVIA Holdings
Oct 9, 2025
Upgrades: Buy
Price Target: $195 → $235
Current: $165.38
Upside: +42.10%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $27.17
Upside: +54.61%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $464.46
Upside: +44.25%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $188.63
Upside: +48.44%
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $282.69
Upside: +62.72%
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $29.16
Upside: -55.41%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $52.14
Upside: +86.04%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $88.45
Upside: +40.20%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $114.37
Upside: +7.55%